| Misty Dawn Ary, MD | |
|
1200 Corporate Dr, 125, Birmingham, AL 35242-2941 | |
| (205) 329-7992 | |
| (205) 329-7999 |
| Full Name | Misty Dawn Ary |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 25 Years |
| Location | 1200 Corporate Dr, Birmingham, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114250420 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD.32546 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Vincent's East | Birmingham, AL | Hospital |
| St Vincent's Birmingham | Birmingham, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Grayson And Associates Pc | 9032108253 | 54 |
News Archive
The suspicion on the part of some experts that Australia's heroin drought has led to an increase in amphetamine use in the last decade, has been scotched by the latest research from the New South Wales Bureau of Crime Statistics and Research.
The American Medical Association's House of Delegates — after a lengthy debate — voted to maintain its support for the health law's individual mandate.
Clinicians need to be sensitive and aware of the unique challenges of women's reproductive health needs in times of conflict, suggests a new review published today (4 July) in The Obstetrician & Gynaecologist.
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.
› Verified 7 days ago
| Entity Name | Grayson And Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194772442 PECOS PAC ID: 9032108253 Enrollment ID: O20040511001342 |
News Archive
The suspicion on the part of some experts that Australia's heroin drought has led to an increase in amphetamine use in the last decade, has been scotched by the latest research from the New South Wales Bureau of Crime Statistics and Research.
The American Medical Association's House of Delegates — after a lengthy debate — voted to maintain its support for the health law's individual mandate.
Clinicians need to be sensitive and aware of the unique challenges of women's reproductive health needs in times of conflict, suggests a new review published today (4 July) in The Obstetrician & Gynaecologist.
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Misty Dawn Ary, MD 1200 Corporate Dr, 125, Birmingham, AL 35242-2941 Ph: (205) 329-7992 | Misty Dawn Ary, MD 1200 Corporate Dr, 125, Birmingham, AL 35242-2941 Ph: (205) 329-7992 |
News Archive
The suspicion on the part of some experts that Australia's heroin drought has led to an increase in amphetamine use in the last decade, has been scotched by the latest research from the New South Wales Bureau of Crime Statistics and Research.
The American Medical Association's House of Delegates — after a lengthy debate — voted to maintain its support for the health law's individual mandate.
Clinicians need to be sensitive and aware of the unique challenges of women's reproductive health needs in times of conflict, suggests a new review published today (4 July) in The Obstetrician & Gynaecologist.
Eisai Co., Ltd. and Purdue Pharma L.P. announced positive topline results from SUNRISE 2, a long-term Phase 3 efficacy and safety evaluation of lemborexant, an investigational agent for sleep-wake regulation currently being studied for the potential treatment of multiple sleep-wake disorders.
› Verified 7 days ago
Rayford W Thweatt, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Marla B Morgan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Robins J Newton, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2700 10th Ave S Ste 400, Birmingham, AL 35205 Phone: 205-918-0507 Fax: 205-930-2716 | |
Mohamed Kazamel, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1717 6th Ave S, Birmingham, AL 35233 Phone: 800-822-8816 | |
Dr. Rodney K Swillie, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3686 Grandview Pkwy Ste 600, Birmingham, AL 35243 Phone: 205-971-3600 Fax: 844-772-0468 | |
Sandra L Frazier, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 619 19t Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Michael Alonzo Lopez, M.D., PH.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1600 6th Ave S # Chb314, Birmingham, AL 35233 Phone: 205-996-7850 |